A PILOT TRIAL OF 5-FU, LEUCOVORIN, AND CISPLATIN WITH OR WITHOUT ADRIAMYCIN IN ADVANCED CANCER

In a pilot trial, we treated patients with solid tumors with 5-FU (5-f luorouracil), leucovorin (LV), and cisplatin (FLP) with Adriamycin in selected patients (FLAP). 5-FU/LV were administered weekly for 6 weeks , with cisplatin at two dose levels (and Adriamycin in some patients) at weeks 1 and 4. Nine patients received FLP; 11 received FLAP. FLP wa s able to be administered with a cisplatin dose of 75 mg/m(2); the max imum-tolerated dose of FLAP included a cisplatin dose of 60 mg/m(2). S ignificant toxicities included granulocytopenia, thrombocytopenia, and diarrhea. Preliminary activity was demonstrated with FLAP in patients with adenocarcinomas of the stomach and gastroesophageal (GE) junctio n. Ongoing trials of FLAP are underway in patients with gastric and GE junction carcinomas in the neoadjuvant and advanced disease settings.